3 Results for "

CBB1007

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "CBB1007" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-15313C
CAS No.: 2070015-03-9
Purity:  97.08%
Target:  

Histone Demethylase

Research Areas:  

Metabolic Disease Cancer

CBB1007 trihydrochloride is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 trihydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 trihydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 trihydrochloride is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma .
loading...
    loading...
Cat. No.: HY-15313B
CAS No.: 2070014-96-7
Purity:  ≥98.0%
Target:  

Histone Demethylase

Research Areas:  

Metabolic Disease Cancer

CBB1007 hydrochloride is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 hydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 hydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 hydrochloride is studied in  non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma .
loading...
    loading...
Cat. No.: HY-15313
CAS No.: 1379573-92-8
Target:  

Histone Demethylase

Research Areas:  

Metabolic Disease Cancer

CBB1007 is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma .
loading...
    loading...